Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Assessing biases of information contained in pedigrees for the classification of BRCA-genetic variants: a study arising from the ENIGMA analytical working group.

Kerkhofs CH, Spurdle AB, Lindsey PJ, Goldgar DE, Gómez-García EB.

Hered Cancer Clin Pract. 2016 Apr 30;14:10. doi: 10.1186/s13053-016-0050-9. eCollection 2016.

2.

Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer.

Henouda S, Bensalem A, Reggad R, Serrar N, Rouabah L, Pujol P.

Dis Markers. 2016;2016:7869095. doi: 10.1155/2016/7869095. Epub 2016 Feb 22.

3.

Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples.

Lee SH, Zhou S, Zhou T, Hong G.

Int J Mol Sci. 2016 Feb 8;17(2). pii: E229. doi: 10.3390/ijms17020229.

4.

Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.

Synowiec A, Wcisło G, Bodnar L, Górski B, Szenajch J, Szarlej-Wcisło K, Szczylik C.

Hered Cancer Clin Pract. 2016 Jan 8;14:1. doi: 10.1186/s13053-015-0044-z. eCollection 2016.

5.

The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective.

Dutil J, Golubeva VA, Pacheco-Torres AL, Diaz-Zabala HJ, Matta JL, Monteiro AN.

Breast Cancer Res Treat. 2015 Dec;154(3):441-53. doi: 10.1007/s10549-015-3629-3. Epub 2015 Nov 12.

6.

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.

Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA, Abbruzzese JL, Laheru D, Diaz LA Jr.

Cancer Chemother Pharmacol. 2015 Sep;76(3):489-98. doi: 10.1007/s00280-015-2788-6. Epub 2015 Jul 1.

PMID:
26126726
7.

Hereditary ovarian cancer: not only BRCA 1 and 2 genes.

Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L.

Biomed Res Int. 2015;2015:341723. doi: 10.1155/2015/341723. Epub 2015 May 17. Review.

8.

Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience.

Asleh-Aburaya K, Fried G.

Springerplus. 2015 Mar 15;4:132. doi: 10.1186/s40064-015-0900-3. eCollection 2015.

9.

Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic.

Ahlborn LB, Dandanell M, Steffensen AY, Jønson L, Nielsen FC, Hansen TV.

Breast Cancer Res Treat. 2015 Apr;150(2):289-98. doi: 10.1007/s10549-015-3313-7. Epub 2015 Feb 28.

10.

Genetic counseling for hereditary breast and ovarian cancer among Puerto Rican women living in the United States.

Scherr CL, Vasquez E, Quinn GP, Vadaparampil ST.

Rev Recent Clin Trials. 2014;9(4):245-53. Review.

11.

Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?

Cheon JY, Mozersky J, Cook-Deegan R.

Genome Med. 2014 Dec 19;6(12):121. doi: 10.1186/s13073-014-0121-3. eCollection 2014.

12.

Breast cancer genetic testing awareness, attitudes and intentions of Latinas living along the US-Mexico border: a qualitative study.

Chalela P, Pagán JA, Su D, Muñoz E, Ramirez AG.

J Community Med Health Educ. 2012;2. pii: 1000152.

13.

Functional classification of BRCA2 DNA variants by splicing assays in a large minigene with 9 exons.

Acedo A, Hernández-Moro C, Curiel-García Á, Díez-Gómez B, Velasco EA.

Hum Mutat. 2015 Feb;36(2):210-21. doi: 10.1002/humu.22725.

14.

Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer.

Torres-Mejía G, Royer R, Llacuachaqui M, Akbari MR, Giuliano AR, Martínez-Matsushita L, Angeles-Llerenas A, Ortega-Olvera C, Ziv E, Lazcano-Ponce E, Phelan CM, Narod SA.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):498-505. doi: 10.1158/1055-9965.EPI-13-0980. Epub 2014 Nov 4.

15.

BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.

Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, Hruban RH, Cote ML, McWilliams RR, Roberts NJ, Cannon-Albright LA, Li D, Moyes K, Wenstrup RJ, Hartman AR, Seminara D, Klein AP, Petersen GM.

Genet Med. 2015 Jul;17(7):569-77. doi: 10.1038/gim.2014.153. Epub 2014 Nov 20.

PMID:
25356972
16.

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.

17.

Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population.

van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK.

Eur J Hum Genet. 2015 May;23(5):588-95. doi: 10.1038/ejhg.2014.161. Epub 2014 Aug 20.

18.

BRCA-associated ovarian cancer: from molecular genetics to risk management.

Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D.

Biomed Res Int. 2014;2014:787143. doi: 10.1155/2014/787143. Epub 2014 Jul 22. Review.

19.

BRCA genetic counseling among at-risk Latinas in New York City: new beliefs shape new generation.

Sussner KM, Edwards T, Villagra C, Rodriguez MC, Thompson HS, Jandorf L, Valdimarsdottir HB.

J Genet Couns. 2015 Feb;24(1):134-48. doi: 10.1007/s10897-014-9746-z. Epub 2014 Aug 15.

20.

Understanding patient and provider perceptions and expectations of genomic medicine.

Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB.

J Surg Oncol. 2015 Jan;111(1):9-17. doi: 10.1002/jso.23712. Epub 2014 Jul 3. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk